Shubham Pant, MD, MBBS, discussed the use of zanidatamab and the HERIZON-BTC-01 trial in HER2-positive biliary tract cancer ...
Antoni Vilaseca Cabo, MD, discusses the rationale behind the phase 1 study evaluating the safety and efficacy of TAR-210 in ...
Joe DePinto, MBA, discusses some of the key challenges to equitable access to cell and gene therapies, especially in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback